TNGX
Tango Therapeutics, Inc.$22.53-0.19 (-0.84%)Prev Close$22.72·MCap$3.83B·P/E—·Vol1.50M·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
17
$7.84M
◆
Net Activity
Net Seller
$7.84M
●
Active Insiders
4
last 12 mo
Over the past 12 months, insider activity at Tango Therapeutics, Inc. (TNGX) has been exclusively selling, with 0 insider purchases totaling $0.00 and 17 insider sales totaling $7.84M. The most recent insider transaction was by Crystal Adam (officer: President, R&D), who sold $660.8K worth of shares on Oct 5, 2026. Tango Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $3.83B.
TNGX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Crystal Adam | officer: President, R&D | Sell | 27,000 | $24.47 | $660.8K | 116,343 |
| Sep 24, 2026 | Newcomb Jessica | officer: Principal Accounting Officer | Sell | 8,200 | $24.22 | $198.6K | 66,621 |
| Sep 3, 2026 | Crystal Adam | officer: President, R&D | Sell | 27,000 | $22.37 | $603.9K | 115,743 |
| Aug 5, 2026 | Crystal Adam | officer: President, R&D | Sell | 27,000 | $27.24 | $735.5K | 137,476 |
| Jul 2, 2026 | Crystal Adam | officer: President, R&D | Sell | 27,000 | $29.59 | $798.9K | 123,114 |
| Jun 3, 2026 | Crystal Adam | officer: President, R&D | Sell | 27,000 | $22.87 | $617.6K | 136,603 |
| May 5, 2026 | Crystal Adam | officer: President, R&D | Sell | 27,000 | $21.23 | $573.1K | 116,843 |
| Apr 16, 2026 | Crystal Adam | officer: President, R&D | Sell | 38,460 | $25.00 | $961.5K | 112,622-25% |
| Mar 27, 2026 | Crystal Adam | officer: President, R&D | Sell | 12,000 | $20.11 | $241.3K | 112,622 |
| Mar 9, 2026 | Crystal Adam | officer: President, R&D | Sell | 20,251 | $15.00 | $303.8K | 112,622 |
| Feb 27, 2026 | Crystal Adam | officer: President, R&D | Sell | 54,345 | $12.77 | $694.2K | 132,873-29% |
| Feb 4, 2026 | Beckman Daniella | officer: Chief Financial Officer | Sell | 10,317 | $12.26 | $126.5K | 184,410 |
| Feb 4, 2026 | Crystal Adam | officer: President, R&D | Sell | 18,452 | $12.26 | $226.3K | 187,419 |
| Feb 4, 2026 | Weber Barbara | director, officer: Director, Executive Chair | Sell | 30,519 | $12.26 | $374.3K | 1,629,587 |
| Feb 2, 2026 | Beckman Daniella | Chief Financial Officer | Sell | 10,317 | $12.26 | $126.5K | 0 |
| Feb 2, 2026 | Crystal Adam | President, R&D | Sell | 18,452 | $12.26 | $226.3K | 0 |
| Feb 2, 2026 | Weber Barbara | Director, Executive Chair | Sell | 30,519 | $12.26 | $374.3K | 0 |
| Feb 6, 2025 | Barry Douglas | General Counsel | Sell | 5,330 | $3.07 | $16.4K | 68,570 |
| Feb 6, 2025 | Beckman Daniella | Chief Financial Officer | Sell | 8,232 | $3.07 | $25.3K | 154,232 |
| Feb 6, 2025 | Crystal Adam | See Remarks | Sell | 14,283 | $3.07 | $43.9K | 165,061 |
| Feb 6, 2025 | Weber Barbara | Chief Executive Officer | Sell | 18,791 | $3.07 | $57.7K | 1,631,264 |
| Nov 18, 2024 | Rothenberg Mace | Buy | 20,000 | $3.70 | $74.0K | 31,250+178% | |
| Nov 8, 2024 | EcoR1 Capital, LLC | 10% Owner | Sell | 2,700,000 | $3.12 | $8.44M2.3% OS | 11,836,178 |
| Nov 7, 2024 | Boxer Capital Management, LLC | Sell | 3,080,000 | $3.14 | $9.67M2.7% OS | 3,610,642-46% | |
| Oct 28, 2024 | Boxer Capital Management, LLC | Sell | 633,000 | $6.87 | $4.35M0.5% OS | 6,690,642 | |
| Oct 23, 2024 | Boxer Capital Management, LLC | Sell | 875,000 | $6.97 | $6.10M0.8% OS | 7,573,642 | |
| Sep 17, 2024 | Third Rock Ventures IV, L.P. | Sell | 67,400 | $10.53 | $709.8K | 16,859,076 | |
| Sep 9, 2024 | Third Rock Ventures IV, L.P. | Sell | 75,000 | $11.56 | $867.1K | 16,926,476 | |
| Sep 4, 2024 | Third Rock Ventures IV, L.P. | Sell | 175,000 | $11.60 | $2.03M | 17,001,476 | |
| Aug 29, 2024 | Third Rock Ventures IV, L.P. | Sell | 25,000 | $11.55 | $288.7K | 17,176,476 | |
| Aug 20, 2024 | Third Rock Ventures IV, L.P. | Sell | 285,000 | $9.95 | $2.84M | 17,351,476 | |
| Aug 1, 2024 | Third Rock Ventures IV, L.P. | Sell | 235,000 | $9.86 | $2.32M | 17,626,476 | |
| Jul 30, 2024 | Third Rock Ventures IV, L.P. | Sell | 50,000 | $9.84 | $491.9K | 17,721,476 | |
| Jul 26, 2024 | Third Rock Ventures IV, L.P. | Sell | 300,599 | $9.83 | $2.96M | 17,872,074 | |
| Jul 24, 2024 | Third Rock Ventures IV, L.P. | Sell | 387,740 | $9.78 | $3.79M | 18,197,074 | |
| Jul 22, 2024 | Third Rock Ventures IV, L.P. | Sell | 191,490 | $9.81 | $1.88M | 18,459,814 | |
| Jul 18, 2024 | Third Rock Ventures IV, L.P. | Sell | 550,171 | $9.79 | $5.39M | 18,651,304 | |
| Jul 2, 2024 | MVA Investors, LLC | Sell | 234,731 | $8.76 | $2.06M | 314,524-43% | |
| Jun 7, 2024 | Calhoun Lesley Ann | Sell | 5,000 | $7.21 | $36.0K | 6,250-44% | |
| Jun 7, 2024 | MVA Investors, LLC | Sell | 140,000 | $7.04 | $985.9K | 420,524 | |
| May 3, 2024 | MVA Investors, LLC | Sell | 210,000 | $7.53 | $1.58M | 618,524-25% | |
| Feb 21, 2024 | Third Rock Ventures IV, L.P. | Sell | 162,500 | $12.00 | $1.95M | 19,201,476 | |
| Feb 8, 2024 | Barry Douglas | General Counsel | Sell | 2,776 | $12.59 | $35.0K | 45,335 |
| Feb 8, 2024 | Beckman Daniella | Chief Financial Officer | Sell | 3,725 | $12.59 | $46.9K | 134,214 |
| Feb 8, 2024 | Crystal Adam | See Remarks | Sell | 8,371 | $12.59 | $105.4K | 123,561 |
| Feb 8, 2024 | Weber Barbara | Chief Executive Officer | Sell | 9,138 | $12.59 | $115.1K | 1,539,624 |
| Nov 2, 2023 | Crystal Adam | See Remarks | Sell | 7,507 | $8.39 | $63.0K | 81,250 |
| Oct 17, 2023 | Boxer Capital, LLC | Buy | 1,250,000 | $6.98 | $8.72M1.1% OS | 8,198,642 | |
| Oct 11, 2023 | Boxer Capital, LLC | Sell | 225,000 | $9.96 | $2.24M | 6,948,642 | |
| Aug 15, 2023 | Boxer Capital, LLC | Buy | 475,000 | $5.15 | $2.45M | 743,542+177% |
Showing 1–50 of 52
1 / 2
TNGX Insider Buying Activity
The following table shows recent insider purchases of Tango Therapeutics, Inc. (TNGX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Nov 18, 2024 | Rothenberg Mace | Buy | 20,000 | $3.70 | $74.0K | 31,250+178% | |
| Oct 17, 2023 | Boxer Capital, LLC | Buy | 1,250,000 | $6.98 | $8.72M1.1% OS | 8,198,642 | |
| Aug 15, 2023 | Boxer Capital, LLC | Buy | 475,000 | $5.15 | $2.45M | 743,542+177% |
TNGX Insider Selling Activity
The following table shows recent insider sales of Tango Therapeutics, Inc. (TNGX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Crystal Adam | officer: President, R&D | Sell | 27,000 | $24.47 | $660.8K | 116,343 |
| Sep 24, 2026 | Newcomb Jessica | officer: Principal Accounting Officer | Sell | 8,200 | $24.22 | $198.6K | 66,621 |
| Sep 3, 2026 | Crystal Adam | officer: President, R&D | Sell | 27,000 | $22.37 | $603.9K | 115,743 |
| Aug 5, 2026 | Crystal Adam | officer: President, R&D | Sell | 27,000 | $27.24 | $735.5K | 137,476 |
| Jul 2, 2026 | Crystal Adam | officer: President, R&D | Sell | 27,000 | $29.59 | $798.9K | 123,114 |
| Jun 3, 2026 | Crystal Adam | officer: President, R&D | Sell | 27,000 | $22.87 | $617.6K | 136,603 |
| May 5, 2026 | Crystal Adam | officer: President, R&D | Sell | 27,000 | $21.23 | $573.1K | 116,843 |
| Apr 16, 2026 | Crystal Adam | officer: President, R&D | Sell | 38,460 | $25.00 | $961.5K | 112,622-25% |
| Mar 27, 2026 | Crystal Adam | officer: President, R&D | Sell | 12,000 | $20.11 | $241.3K | 112,622 |
| Mar 9, 2026 | Crystal Adam | officer: President, R&D | Sell | 20,251 | $15.00 | $303.8K | 112,622 |
| Feb 27, 2026 | Crystal Adam | officer: President, R&D | Sell | 54,345 | $12.77 | $694.2K | 132,873-29% |
| Feb 4, 2026 | Beckman Daniella | officer: Chief Financial Officer | Sell | 10,317 | $12.26 | $126.5K | 184,410 |
| Feb 4, 2026 | Crystal Adam | officer: President, R&D | Sell | 18,452 | $12.26 | $226.3K | 187,419 |
| Feb 4, 2026 | Weber Barbara | director, officer: Director, Executive Chair | Sell | 30,519 | $12.26 | $374.3K | 1,629,587 |
| Feb 2, 2026 | Beckman Daniella | Chief Financial Officer | Sell | 10,317 | $12.26 | $126.5K | 0 |
| Feb 2, 2026 | Crystal Adam | President, R&D | Sell | 18,452 | $12.26 | $226.3K | 0 |
| Feb 2, 2026 | Weber Barbara | Director, Executive Chair | Sell | 30,519 | $12.26 | $374.3K | 0 |
| Feb 6, 2025 | Barry Douglas | General Counsel | Sell | 5,330 | $3.07 | $16.4K | 68,570 |
| Feb 6, 2025 | Beckman Daniella | Chief Financial Officer | Sell | 8,232 | $3.07 | $25.3K | 154,232 |
| Feb 6, 2025 | Crystal Adam | See Remarks | Sell | 14,283 | $3.07 | $43.9K | 165,061 |
| Feb 6, 2025 | Weber Barbara | Chief Executive Officer | Sell | 18,791 | $3.07 | $57.7K | 1,631,264 |
| Nov 8, 2024 | EcoR1 Capital, LLC | 10% Owner | Sell | 2,700,000 | $3.12 | $8.44M2.3% OS | 11,836,178 |
| Nov 7, 2024 | Boxer Capital Management, LLC | Sell | 3,080,000 | $3.14 | $9.67M2.7% OS | 3,610,642-46% | |
| Oct 28, 2024 | Boxer Capital Management, LLC | Sell | 633,000 | $6.87 | $4.35M0.5% OS | 6,690,642 | |
| Oct 23, 2024 | Boxer Capital Management, LLC | Sell | 875,000 | $6.97 | $6.10M0.8% OS | 7,573,642 | |
| Sep 17, 2024 | Third Rock Ventures IV, L.P. | Sell | 67,400 | $10.53 | $709.8K | 16,859,076 | |
| Sep 9, 2024 | Third Rock Ventures IV, L.P. | Sell | 75,000 | $11.56 | $867.1K | 16,926,476 | |
| Sep 4, 2024 | Third Rock Ventures IV, L.P. | Sell | 175,000 | $11.60 | $2.03M | 17,001,476 | |
| Aug 29, 2024 | Third Rock Ventures IV, L.P. | Sell | 25,000 | $11.55 | $288.7K | 17,176,476 | |
| Aug 20, 2024 | Third Rock Ventures IV, L.P. | Sell | 285,000 | $9.95 | $2.84M | 17,351,476 | |
| Aug 1, 2024 | Third Rock Ventures IV, L.P. | Sell | 235,000 | $9.86 | $2.32M | 17,626,476 | |
| Jul 30, 2024 | Third Rock Ventures IV, L.P. | Sell | 50,000 | $9.84 | $491.9K | 17,721,476 | |
| Jul 26, 2024 | Third Rock Ventures IV, L.P. | Sell | 300,599 | $9.83 | $2.96M | 17,872,074 | |
| Jul 24, 2024 | Third Rock Ventures IV, L.P. | Sell | 387,740 | $9.78 | $3.79M | 18,197,074 | |
| Jul 22, 2024 | Third Rock Ventures IV, L.P. | Sell | 191,490 | $9.81 | $1.88M | 18,459,814 | |
| Jul 18, 2024 | Third Rock Ventures IV, L.P. | Sell | 550,171 | $9.79 | $5.39M | 18,651,304 | |
| Jul 2, 2024 | MVA Investors, LLC | Sell | 234,731 | $8.76 | $2.06M | 314,524-43% | |
| Jun 7, 2024 | Calhoun Lesley Ann | Sell | 5,000 | $7.21 | $36.0K | 6,250-44% | |
| Jun 7, 2024 | MVA Investors, LLC | Sell | 140,000 | $7.04 | $985.9K | 420,524 | |
| May 3, 2024 | MVA Investors, LLC | Sell | 210,000 | $7.53 | $1.58M | 618,524-25% | |
| Feb 21, 2024 | Third Rock Ventures IV, L.P. | Sell | 162,500 | $12.00 | $1.95M | 19,201,476 | |
| Feb 8, 2024 | Barry Douglas | General Counsel | Sell | 2,776 | $12.59 | $35.0K | 45,335 |
| Feb 8, 2024 | Beckman Daniella | Chief Financial Officer | Sell | 3,725 | $12.59 | $46.9K | 134,214 |
| Feb 8, 2024 | Crystal Adam | See Remarks | Sell | 8,371 | $12.59 | $105.4K | 123,561 |
| Feb 8, 2024 | Weber Barbara | Chief Executive Officer | Sell | 9,138 | $12.59 | $115.1K | 1,539,624 |
| Nov 2, 2023 | Crystal Adam | See Remarks | Sell | 7,507 | $8.39 | $63.0K | 81,250 |
| Oct 11, 2023 | Boxer Capital, LLC | Sell | 225,000 | $9.96 | $2.24M | 6,948,642 |
TNGX Insiders
Similar Stocks to TNGX
MRNA
Moderna, Inc.
$227.10+2.43%
$85.50B
REGN
Regeneron Pharmaceuticals, Inc.
$963.34+3.82%
$83.15B
RVMD
Revolution Medicines, Inc.
$189.18-1.12%
$39.42B
ALNY
Alnylam Pharmaceuticals, Inc.
$160.28-2.86%
$30.46B
UTHR
United Therapeutics Corporation
$596.63-0.35%
$25.15B
INCY
Incyte Corporation
$119.33-0.88%
$23.69B
INSM
Insmed Incorporated
$110.27-2.06%
$21.18B
EXEL
Exelixis, Inc.
$71.30+2.67%
$16.64B